RaySearch releases RayStation 2024A

RaySearch Laboratories AB (publ) announces the launch of RayStation®* 2024A, the latest version of the company’s comprehensive treatment planning system. The new version brings several enhancements to important clinical workflows.

RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs. The new version of the treatment planning system adds the possibility to select fixation and support devices per plan and sub-plan. This adds improved flexibility when making combined treatment plans for a patient, for example photon-proton treatments where different treatment couches are used. Now, all needed couches and support devices can be modeled for a patient and the devices to include can easily be selected per plan. RayStation 2024A also brings the possibility to define clinical planning goals for both the combined plan and the constituent sub-plans, and evaluate correspondingly. This enhances the workflow further for evaluation of combinations of treatment plans.

In adaptive therapy planning, daily images are used to update the treatment plan to account for anatomical changes that occur during the course of treatment, such as tumor shrinkage, weight loss or organ motion. RayStation is specifically designed to make adaptive therapy faster and easier in clinical practice. The workflow for enhancing daily images to allow for accurate dose computation is further improved with RayStation 2024A.

RayStation 2024A also enhances the integration with the oncology analytics system RayIntelligence. RayIntelligence absorbs RayStation data automatically and enables users to monitor and understand the current state of the clinic and its treatments as well as provides insights on how to improve efficiency and treatment quality going forward.

Other improvements include adjustments to improve and ease transfer of treatment plans to various oncology information systems for delivery and faster saving of plan data, as well as a new tool used for segmentation of blood vessels in the lungs.

Johan Löf, founder and CEO, RaySearch, says: “Further enhancing the capabilities of multi-modality treatments is key for RaySearch in the ambition to provide tools to create the best treatment plans for cancer patients. With RayStation 2024A we also continue with improvements within fast adaptive re-planning, which will be an important focus area during the coming years.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.
Anna Kazanchyan, MD, Founder and CEO of Saghmos Therapeutics. "We are very pleased to announce the Notice of Allowance for our second patent, which will enhance the long-term value of ST-62516. Saghmos continues to build its intellectual property estate."

By using this website you agree to accept Medical Device News Magazine Privacy Policy